5-ethyl-2-[(4-methylnaphthalen-1-yl)carbonyl]-1H,2H,3H,4H,5H-pyrido[4,3-b]indole | 1447697-52-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-ethyl-2-[(4-methylnaphthalen-1-yl)carbonyl]-1H,2H,3H,4H,5H-pyrido[4,3-b]indole
• 英文别名: (5-ethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-2-yl)-(4-methylnaphthalen-1-yl)methanone
• CAS: 1447697-52-0
• 化学式: C₂₅H₂₄N₂O
• 分子量: 368.478
• InChiKey: JGNDICDZEWTBHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  25.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1,3,4,5-四氢-2H-吡啶并[4,3-b]吲哚-2-甲酸乙酯 在 potassium permanganate 、 水 、 sodium hydride 、 potassium hydroxide 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 51.5h， 生成 5-ethyl-2-[(4-methylnaphthalen-1-yl)carbonyl]-1H,2H,3H,4H,5H-pyrido[4,3-b]indole
  参考文献：
  名称：

  [EN] MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS
  [FR] CARBAZOLES MODIFIÉS UTILES COMME AGENTS THÉRAPEUTIQUES

  摘要：

  这份披露涉及针对微管的化合物，包括它们的药物组合物，以及使用这些化合物和组合物治疗疾病的方法。更具体地说，这份披露涉及改良的咔唑化合物及其药物组合物，使用这些化合物针对微管的方法，以及治疗受微管破坏影响的疾病的方法。

  公开号：

  WO2019241451A1

文献信息

• [EN] MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS<br/>[FR] CARBAZOLES MODIFIÉS UTILES COMME AGENTS THÉRAPEUTIQUES
  申请人：UNIV WASHINGTON

  公开号：WO2019241451A1

  公开（公告）日：2019-12-19

  This disclosure relates to compounds that target microtubules, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases. More particularly, this disclosure relates to modified carbazole compounds and pharmaceutical compositions thereof, methods of targeting microtubules with these compounds, and methods of treating diseases affected by microtubule disruption.

  这份披露涉及针对微管的化合物，包括它们的药物组合物，以及使用这些化合物和组合物治疗疾病的方法。更具体地说，这份披露涉及改良的咔唑化合物及其药物组合物，使用这些化合物针对微管的方法，以及治疗受微管破坏影响的疾病的方法。
• MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS
  申请人：UNIVERSITY OF WASHINGTON

  公开号：US20210094949A1

  公开（公告）日：2021-04-01

  This disclosure relates to compounds that target microtubules, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases. More particularly, this disclosure relates to modified carbazole compounds and pharmaceutical compositions thereof, methods of targeting microtubules with these compounds, and methods of treating diseases affected by microtubule disruption.
• [EN] COMPOSITIONS AND METHODS FOR TREATING MALIGNANT ASTROCYTOMAS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DESTINÉS AU TRAITEMENT D'ASTROCYTOMES MALINS
  申请人：UNIV WASHINGTON CT COMMERCIALI

  公开号：WO2013106460A2

  公开（公告）日：2013-07-18

  The disclosure provides methods of treating glioblastoma, methods of screening for compounds that treat glioblastoma, and pharmaceutical compositions useful in the treatment of glioblastoma.
• Modified carbazoles destabilize microtubules and kill glioblastoma multiform cells
  作者：Philippe Diaz、Eric Horne、Cong Xu、Ernest Hamel、Michael Wagenbach、Ravil R. Petrov、Benjamin Uhlenbruck、Brian Haas、Parvinder Hothi、Linda Wordeman、Rick Gussio、Nephi Stella

  DOI：10.1016/j.ejmech.2018.09.026

  日期：2018.11

  Small molecules that target microtubules (MTs) represent promising therapeutics to treat certain types of cancer, including glioblastoma multiform (GBM). We synthesized modified carbazoles and evaluated their antitumor activity in GBM cells in culture. Modified carbazoles with an ethyl moiety linked to the nitrogen of the carbazole and a carbonyl moiety linked to distinct biaromatic rings exhibited remarkably different killing activities in human GBM cell lines and patient-derived GBM cells, with IC50 values from 67 to > 10,000 nM. Measures of the activity of modified carbazoles with tubulin and microtubules coupled to molecular docking studies show that these compounds bind to the colchicine site of tubulin in a unique low interaction space that inhibits tubulin assembly. The modified carbazoles reported here represent novel chemical tools to better understand how small molecules disrupt MT functions and kill devastating cancers such as GBM. (C) 2018 Elsevier Masson SAS. All rights reserved.